308 related articles for article (PubMed ID: 31126963)
1. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
Lucchini E; Zaja F; Bussel J
Haematologica; 2019 Jun; 104(6):1124-1135. PubMed ID: 31126963
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study.
Tjønnfjord E; Holme PA; Darne B; Khelif A; Waage A; Michel M; Ben Romdhan N; Ghanima W
Br J Haematol; 2020 Nov; 191(3):460-465. PubMed ID: 32342497
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children.
Dai WJ; Zhang RR; Yang XC; Yuan YF
Eur Rev Med Pharmacol Sci; 2015 Jul; 19(13):2379-83. PubMed ID: 26214772
[TBL] [Abstract][Full Text] [Related]
4. Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature.
Al-Husban N; Al-Kuran O
J Med Case Rep; 2018 Jun; 12(1):147. PubMed ID: 29855343
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
Oved JH; Lee CSY; Bussel JB
J Pediatr; 2017 Dec; 191():225-231. PubMed ID: 29173312
[TBL] [Abstract][Full Text] [Related]
6. Reemergence of Splenectomy for ITP Second-line Treatment?
Chater C; Terriou L; Duhamel A; Launay D; Chambon JP; Pruvot FR; Rogosnitzky M; Zerbib P
Ann Surg; 2016 Nov; 264(5):772-777. PubMed ID: 27741009
[TBL] [Abstract][Full Text] [Related]
7. [Current topics in primary immune thrombocytopenia].
Tomiyama Y
Rinsho Ketsueki; 2017; 58(5):537-541. PubMed ID: 28592772
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
11. Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia.
Gudbrandsdottir S; Brimnes M; Køllgaard T; Hasselbalch HC; Nielsen CH
Eur J Haematol; 2018 Jan; 100(1):45-52. PubMed ID: 28960473
[TBL] [Abstract][Full Text] [Related]
12. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP
Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
[TBL] [Abstract][Full Text] [Related]
14. [Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus].
Lehembre S; Macario-Barrel A; Musette P; Carvalho P; Joly P
Ann Dermatol Venereol; 2006 Jan; 133(1):53-5. PubMed ID: 16495854
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of primary immune thrombocytopenia in adults.
Ejaz A; Radia D
Br J Hosp Med (Lond); 2019 Apr; 80(4):C54-C57. PubMed ID: 30951423
[No Abstract] [Full Text] [Related]
16. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura.
Gall B; Yee A; Berry B; Bircham D; Hayashi A; Dansereau J; Hart J
J Obstet Gynaecol Can; 2010 Dec; 32(12):1167-1171. PubMed ID: 21176329
[TBL] [Abstract][Full Text] [Related]
17. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
[TBL] [Abstract][Full Text] [Related]
18. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
López MF; Mingot ME; Valcárcel D; Vicente García V; Perrin A; Campos Tapias I
Med Clin (Barc); 2015 May; 144(9):389-96. PubMed ID: 24565604
[TBL] [Abstract][Full Text] [Related]
19. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
Cooper N; Evangelista ML; Amadori S; Stasi R
Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
[TBL] [Abstract][Full Text] [Related]
20. [Use of rituximab in resistant thrombocytopenic purpura].
Zambrano-Velarde MA; de la O-Peña D; Chávez-Peña Q; Bedolla-Barajas M
Rev Med Inst Mex Seguro Soc; 2012; 50(2):203-8. PubMed ID: 22882991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
